-
Achillion Announces Initiation of Phase 1 Trial of ACH-2684 for the Treatment of Hepatitis C
Wednesday, May 25, 2011 - 7:04am | 133Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that the Company has begun dosing in a Phase 1 clinical trial of ACH-2684, a novel pan-genotypic protease inhibitor being developed for the treatment of chronic hepatitis C virus infection. The Phase 1 clinical study is a randomized,...
-
Athersys Announces Positive Interim Results From Ongoing Phase I Study of MultiStem(R)
Wednesday, May 25, 2011 - 7:03am | 265Athersys (Nasdaq: ATHX) today announced positive interim results from an ongoing Phase I clinical trial of MultiStem^®, its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants for the treatment of leukemia and related conditions. The study...
-
Mad Money Lightning Round OT: Cramer Likes BYD (DF, BYD, ARIA)
Tuesday, May 24, 2011 - 7:39pm | 149Jim Cramer said on CNBC's Mad Money Lightning Round OT that you shouldn't buy Dean Foods Company (NYSE: DF), because it had a huge run recently. Dean Foods Company (DF) gained 0.22%, and it closed at $13.51. Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) is a good speculative stock, and Cramer wants...
-
More Spying on Elite Funds - Part 2
Tuesday, May 24, 2011 - 7:05pm | 1695A follow-up to my last comment on spying on elite funds. We begin with an article by Naked Value on Seeking Alpha, Paulson & Co.'s Biggest Buy, Biggest Sell and Top Holdings. You'll notice that unlike Dodge and Cox, Paulson & Co sold all their Pfizer shares, and initiated a new position in...
-
Options Brief: Geron Corporation
Tuesday, May 24, 2011 - 1:29pm | 78Shares of Geron Corporation (NASDAQ: GERN) are lower on the session by 3.11%, trading at $4.36. Overall call volume is now running at 2.76x the daily average, with 70% of all calls traded being purchases on the offer. 3,096 contracts have traded on the session so far. Geron Corporation is a...
-
Biotech/Pharma Investor Trading Alert; BioSante Pharmaceuticals, Inc. Trades up Over 6% on Over 8 Million Shares
Tuesday, May 24, 2011 - 12:54pm | 878Point Roberts, WA, LINCOLNSHIRE, Ill - May 24, 2011 – Investorideas.com, a leader in sector stock research for independent investors, issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX). The stock closed trading May 23rd, at $2.80, up $ 0.17 (6....
-
Benzinga's Volume Movers
Tuesday, May 24, 2011 - 10:28am | 156Perfect World Co Ltd (NASDAQ: PWRD) shares surged 12.19% to $26.87 at 10:25 am. The volume of PWRD shares traded was 395% higher than normal. PWRD reported upbeat Q1 profit. GT Solar International Inc (NASDAQ: SOLR) shares moved up 8.95% to $12.66. The volume of SOLR shares traded was 362% higher...
-
Genomic Health Announces Positive Preliminary Results of Oncotype DX Study in DCIS Breast Cancer
Tuesday, May 24, 2011 - 9:05am | 130Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a study of Oncotype DX® in patients with DCIS, a clinical trials cooperative group supported by the National Cancer Institute. The ECOG 5194 validation study met its primary endpoint by demonstrating that a pre-...
-
Upgrades Downgrades, Stocks to Watch May 24
Tuesday, May 24, 2011 - 8:27am | 303Pharmasset, Inc. (VRUS) JP Morgan raised Pharmasset's price target to $200 based on building momentum for the nuc class of Hep C therapies following the recent EASL - Massive upgrade - stock trading 102.55 up 5 in the pre market Post Market Headlines United States Oil Fund LP (USO) GS Raises its...
-
Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Cetuximab
Tuesday, May 24, 2011 - 8:03am | 70Oncothyreon Inc. (Nasdaq: ONTY) today announced it has initiated the Phase 2 portion of its ongoing Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab following successful completion of the Phase 1 dose escalation portion of the study. PX-866 is a small...
-
UPDATE: J.P. Morgan Raises PT on Vertex Pharmaceuticals to $53
Tuesday, May 24, 2011 - 7:33am | 116J.P. Morgan is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), raising its PT from $46 to $53. In a note to clients, J.P. Morgan writes, "Overall, we view Incivek pricing as an upside surprise but one that was widely anticipated by the market, and, at the end of the day, the...
-
J.P. Morgan Raises PT On VRUS To $200
Tuesday, May 24, 2011 - 7:31am | 224J.P. Morgan has raised its price target on Pharmasset (NASDAQ: VRUS) from $100 to $200 in light of “Biotech Week”Day 2 and portfolio analysis of the stock. According to J.P. Morgan, “[The change in price target] is based on consistent positive feedback from the Hep C arena and building momentum...
-
Bank Of America Comments On Vertex Pharmaceuticals FDA Approvals
Tuesday, May 24, 2011 - 7:30am | 191According to Bank of America, Vertex Pharmaceuticals (NASDAQ: VRTX) will capture the full value of Incivek therapy in 1 quarter vs 3 quarters for MRK, so the dollar market share for VRTX with our assumptions is significantly higher at 70-80%. Bank of America said that with the recent FDA approvals...
-
PDL BioPharma Issues Redemption Notice for Its 2.00% Convertible Senior Notes Due February 15, 2012
Tuesday, May 24, 2011 - 7:04am | 133PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that on June 30, 2011, it will redeem all of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the Notes). Holders of the Notes have been provided notice of the redemption by The Bank of New York Mellon, the trustee...
-
JP Morgan Raises PT On Vertex Pharmaceuticals To $53
Tuesday, May 24, 2011 - 6:22am | 27JP Morgan has raised the price target on Vertex Pharmaceuticals (NASDAQ: VRTX) from $46 to $53 and maintains its Neutral rating.